The global Immune Mediated Tumor Killing Assays Service market size was valued at US$ 1430 million in 2024 and is forecast to a readjusted size of USD 2547 million by 2031 with a CAGR of 8.7% during review period.
Immune cell killing may involve components of the innate and adaptive immune systems, including natural killer (NK) cells, cytotoxic T cells (MHC-dependent), antibodies secreted by B lymphocytes, engineered antibodies such as bispecific antibodies and bispecific T-cell engagers (BiTEs), and genetically engineered T cells directed against specific tumor antigens (e.g., CAR-T, MHC-independent).
This report is a detailed and comprehensive analysis for global Immune Mediated Tumor Killing Assays Service market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Immune Mediated Tumor Killing Assays Service market size and forecasts, in consumption value ($ Million), 2020-2031
Global Immune Mediated Tumor Killing Assays Service market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Immune Mediated Tumor Killing Assays Service market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Immune Mediated Tumor Killing Assays Service market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Immune Mediated Tumor Killing Assays Service
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Immune Mediated Tumor Killing Assays Service market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Agilent, Laboratories, Explicyte, Reaction Biology, Axion BioSystems, Sartorius, ICE Bioscience, Shanghai Saily Biotechnology, ProBio, Charles River, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 segmentation
Immune Mediated Tumor Killing Assays Service market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Cytotoxic T Cell Assay
Natural Killer (NK) Cell Assay
Other
麻豆原创 segment by Application
Cancer Research
Infectious Disease Research
Immunotherapy Development
麻豆原创 segment by players, this report covers
Agilent
Laboratories
Explicyte
Reaction Biology
Axion BioSystems
Sartorius
ICE Bioscience
Shanghai Saily Biotechnology
ProBio
Charles River
Imodels
Xeno Diagnostics
Cyagen
MarinBio
Pharmalegacy
Celentyx
Crown Bioscience
Cellomatics Biosciences
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Immune Mediated Tumor Killing Assays Service product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Immune Mediated Tumor Killing Assays Service, with revenue, gross margin, and global market share of Immune Mediated Tumor Killing Assays Service from 2020 to 2025.
Chapter 3, the Immune Mediated Tumor Killing Assays Service competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Immune Mediated Tumor Killing Assays Service market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Immune Mediated Tumor Killing Assays Service.
Chapter 13, to describe Immune Mediated Tumor Killing Assays Service research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Immune Mediated Tumor Killing Assays Service by Type
1.3.1 Overview: Global Immune Mediated Tumor Killing Assays Service 麻豆原创 Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Immune Mediated Tumor Killing Assays Service Consumption Value 麻豆原创 Share by Type in 2024
1.3.3 Cytotoxic T Cell Assay
1.3.4 Natural Killer (NK) Cell Assay
1.3.5 Other
1.4 Global Immune Mediated Tumor Killing Assays Service 麻豆原创 by Application
1.4.1 Overview: Global Immune Mediated Tumor Killing Assays Service 麻豆原创 Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Cancer Research
1.4.3 Infectious Disease Research
1.4.4 Immunotherapy Development
1.5 Global Immune Mediated Tumor Killing Assays Service 麻豆原创 Size & Forecast
1.6 Global Immune Mediated Tumor Killing Assays Service 麻豆原创 Size and Forecast by Region
1.6.1 Global Immune Mediated Tumor Killing Assays Service 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Immune Mediated Tumor Killing Assays Service 麻豆原创 Size by Region, (2020-2031)
1.6.3 North America Immune Mediated Tumor Killing Assays Service 麻豆原创 Size and Prospect (2020-2031)
1.6.4 Europe Immune Mediated Tumor Killing Assays Service 麻豆原创 Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Immune Mediated Tumor Killing Assays Service 麻豆原创 Size and Prospect (2020-2031)
1.6.6 South America Immune Mediated Tumor Killing Assays Service 麻豆原创 Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Immune Mediated Tumor Killing Assays Service 麻豆原创 Size and Prospect (2020-2031)
2 Company Profiles
2.1 Agilent
2.1.1 Agilent Details
2.1.2 Agilent Major Business
2.1.3 Agilent Immune Mediated Tumor Killing Assays Service Product and Solutions
2.1.4 Agilent Immune Mediated Tumor Killing Assays Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Agilent Recent Developments and Future Plans
2.2 Laboratories
2.2.1 Laboratories Details
2.2.2 Laboratories Major Business
2.2.3 Laboratories Immune Mediated Tumor Killing Assays Service Product and Solutions
2.2.4 Laboratories Immune Mediated Tumor Killing Assays Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 Laboratories Recent Developments and Future Plans
2.3 Explicyte
2.3.1 Explicyte Details
2.3.2 Explicyte Major Business
2.3.3 Explicyte Immune Mediated Tumor Killing Assays Service Product and Solutions
2.3.4 Explicyte Immune Mediated Tumor Killing Assays Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 Explicyte Recent Developments and Future Plans
2.4 Reaction Biology
2.4.1 Reaction Biology Details
2.4.2 Reaction Biology Major Business
2.4.3 Reaction Biology Immune Mediated Tumor Killing Assays Service Product and Solutions
2.4.4 Reaction Biology Immune Mediated Tumor Killing Assays Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Reaction Biology Recent Developments and Future Plans
2.5 Axion BioSystems
2.5.1 Axion BioSystems Details
2.5.2 Axion BioSystems Major Business
2.5.3 Axion BioSystems Immune Mediated Tumor Killing Assays Service Product and Solutions
2.5.4 Axion BioSystems Immune Mediated Tumor Killing Assays Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Axion BioSystems Recent Developments and Future Plans
2.6 Sartorius
2.6.1 Sartorius Details
2.6.2 Sartorius Major Business
2.6.3 Sartorius Immune Mediated Tumor Killing Assays Service Product and Solutions
2.6.4 Sartorius Immune Mediated Tumor Killing Assays Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 Sartorius Recent Developments and Future Plans
2.7 ICE Bioscience
2.7.1 ICE Bioscience Details
2.7.2 ICE Bioscience Major Business
2.7.3 ICE Bioscience Immune Mediated Tumor Killing Assays Service Product and Solutions
2.7.4 ICE Bioscience Immune Mediated Tumor Killing Assays Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 ICE Bioscience Recent Developments and Future Plans
2.8 Shanghai Saily Biotechnology
2.8.1 Shanghai Saily Biotechnology Details
2.8.2 Shanghai Saily Biotechnology Major Business
2.8.3 Shanghai Saily Biotechnology Immune Mediated Tumor Killing Assays Service Product and Solutions
2.8.4 Shanghai Saily Biotechnology Immune Mediated Tumor Killing Assays Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 Shanghai Saily Biotechnology Recent Developments and Future Plans
2.9 ProBio
2.9.1 ProBio Details
2.9.2 ProBio Major Business
2.9.3 ProBio Immune Mediated Tumor Killing Assays Service Product and Solutions
2.9.4 ProBio Immune Mediated Tumor Killing Assays Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 ProBio Recent Developments and Future Plans
2.10 Charles River
2.10.1 Charles River Details
2.10.2 Charles River Major Business
2.10.3 Charles River Immune Mediated Tumor Killing Assays Service Product and Solutions
2.10.4 Charles River Immune Mediated Tumor Killing Assays Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.10.5 Charles River Recent Developments and Future Plans
2.11 Imodels
2.11.1 Imodels Details
2.11.2 Imodels Major Business
2.11.3 Imodels Immune Mediated Tumor Killing Assays Service Product and Solutions
2.11.4 Imodels Immune Mediated Tumor Killing Assays Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.11.5 Imodels Recent Developments and Future Plans
2.12 Xeno Diagnostics
2.12.1 Xeno Diagnostics Details
2.12.2 Xeno Diagnostics Major Business
2.12.3 Xeno Diagnostics Immune Mediated Tumor Killing Assays Service Product and Solutions
2.12.4 Xeno Diagnostics Immune Mediated Tumor Killing Assays Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.12.5 Xeno Diagnostics Recent Developments and Future Plans
2.13 Cyagen
2.13.1 Cyagen Details
2.13.2 Cyagen Major Business
2.13.3 Cyagen Immune Mediated Tumor Killing Assays Service Product and Solutions
2.13.4 Cyagen Immune Mediated Tumor Killing Assays Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.13.5 Cyagen Recent Developments and Future Plans
2.14 MarinBio
2.14.1 MarinBio Details
2.14.2 MarinBio Major Business
2.14.3 MarinBio Immune Mediated Tumor Killing Assays Service Product and Solutions
2.14.4 MarinBio Immune Mediated Tumor Killing Assays Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.14.5 MarinBio Recent Developments and Future Plans
2.15 Pharmalegacy
2.15.1 Pharmalegacy Details
2.15.2 Pharmalegacy Major Business
2.15.3 Pharmalegacy Immune Mediated Tumor Killing Assays Service Product and Solutions
2.15.4 Pharmalegacy Immune Mediated Tumor Killing Assays Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.15.5 Pharmalegacy Recent Developments and Future Plans
2.16 Celentyx
2.16.1 Celentyx Details
2.16.2 Celentyx Major Business
2.16.3 Celentyx Immune Mediated Tumor Killing Assays Service Product and Solutions
2.16.4 Celentyx Immune Mediated Tumor Killing Assays Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.16.5 Celentyx Recent Developments and Future Plans
2.17 Crown Bioscience
2.17.1 Crown Bioscience Details
2.17.2 Crown Bioscience Major Business
2.17.3 Crown Bioscience Immune Mediated Tumor Killing Assays Service Product and Solutions
2.17.4 Crown Bioscience Immune Mediated Tumor Killing Assays Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.17.5 Crown Bioscience Recent Developments and Future Plans
2.18 Cellomatics Biosciences
2.18.1 Cellomatics Biosciences Details
2.18.2 Cellomatics Biosciences Major Business
2.18.3 Cellomatics Biosciences Immune Mediated Tumor Killing Assays Service Product and Solutions
2.18.4 Cellomatics Biosciences Immune Mediated Tumor Killing Assays Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.18.5 Cellomatics Biosciences Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Immune Mediated Tumor Killing Assays Service Revenue and Share by Players (2020-2025)
3.2 麻豆原创 Share Analysis (2024)
3.2.1 麻豆原创 Share of Immune Mediated Tumor Killing Assays Service by Company Revenue
3.2.2 Top 3 Immune Mediated Tumor Killing Assays Service Players 麻豆原创 Share in 2024
3.2.3 Top 6 Immune Mediated Tumor Killing Assays Service Players 麻豆原创 Share in 2024
3.3 Immune Mediated Tumor Killing Assays Service 麻豆原创: Overall Company Footprint Analysis
3.3.1 Immune Mediated Tumor Killing Assays Service 麻豆原创: Region Footprint
3.3.2 Immune Mediated Tumor Killing Assays Service 麻豆原创: Company Product Type Footprint
3.3.3 Immune Mediated Tumor Killing Assays Service 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Immune Mediated Tumor Killing Assays Service Consumption Value and 麻豆原创 Share by Type (2020-2025)
4.2 Global Immune Mediated Tumor Killing Assays Service 麻豆原创 Forecast by Type (2026-2031)
5 麻豆原创 Size Segment by Application
5.1 Global Immune Mediated Tumor Killing Assays Service Consumption Value 麻豆原创 Share by Application (2020-2025)
5.2 Global Immune Mediated Tumor Killing Assays Service 麻豆原创 Forecast by Application (2026-2031)
6 North America
6.1 North America Immune Mediated Tumor Killing Assays Service Consumption Value by Type (2020-2031)
6.2 North America Immune Mediated Tumor Killing Assays Service 麻豆原创 Size by Application (2020-2031)
6.3 North America Immune Mediated Tumor Killing Assays Service 麻豆原创 Size by Country
6.3.1 North America Immune Mediated Tumor Killing Assays Service Consumption Value by Country (2020-2031)
6.3.2 United States Immune Mediated Tumor Killing Assays Service 麻豆原创 Size and Forecast (2020-2031)
6.3.3 Canada Immune Mediated Tumor Killing Assays Service 麻豆原创 Size and Forecast (2020-2031)
6.3.4 Mexico Immune Mediated Tumor Killing Assays Service 麻豆原创 Size and Forecast (2020-2031)
7 Europe
7.1 Europe Immune Mediated Tumor Killing Assays Service Consumption Value by Type (2020-2031)
7.2 Europe Immune Mediated Tumor Killing Assays Service Consumption Value by Application (2020-2031)
7.3 Europe Immune Mediated Tumor Killing Assays Service 麻豆原创 Size by Country
7.3.1 Europe Immune Mediated Tumor Killing Assays Service Consumption Value by Country (2020-2031)
7.3.2 Germany Immune Mediated Tumor Killing Assays Service 麻豆原创 Size and Forecast (2020-2031)
7.3.3 France Immune Mediated Tumor Killing Assays Service 麻豆原创 Size and Forecast (2020-2031)
7.3.4 United Kingdom Immune Mediated Tumor Killing Assays Service 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Russia Immune Mediated Tumor Killing Assays Service 麻豆原创 Size and Forecast (2020-2031)
7.3.6 Italy Immune Mediated Tumor Killing Assays Service 麻豆原创 Size and Forecast (2020-2031)
8 Asia-Pacific
8.1 Asia-Pacific Immune Mediated Tumor Killing Assays Service Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Immune Mediated Tumor Killing Assays Service Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Immune Mediated Tumor Killing Assays Service 麻豆原创 Size by Region
8.3.1 Asia-Pacific Immune Mediated Tumor Killing Assays Service Consumption Value by Region (2020-2031)
8.3.2 China Immune Mediated Tumor Killing Assays Service 麻豆原创 Size and Forecast (2020-2031)
8.3.3 Japan Immune Mediated Tumor Killing Assays Service 麻豆原创 Size and Forecast (2020-2031)
8.3.4 South Korea Immune Mediated Tumor Killing Assays Service 麻豆原创 Size and Forecast (2020-2031)
8.3.5 India Immune Mediated Tumor Killing Assays Service 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Southeast Asia Immune Mediated Tumor Killing Assays Service 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Australia Immune Mediated Tumor Killing Assays Service 麻豆原创 Size and Forecast (2020-2031)
9 South America
9.1 South America Immune Mediated Tumor Killing Assays Service Consumption Value by Type (2020-2031)
9.2 South America Immune Mediated Tumor Killing Assays Service Consumption Value by Application (2020-2031)
9.3 South America Immune Mediated Tumor Killing Assays Service 麻豆原创 Size by Country
9.3.1 South America Immune Mediated Tumor Killing Assays Service Consumption Value by Country (2020-2031)
9.3.2 Brazil Immune Mediated Tumor Killing Assays Service 麻豆原创 Size and Forecast (2020-2031)
9.3.3 Argentina Immune Mediated Tumor Killing Assays Service 麻豆原创 Size and Forecast (2020-2031)
10 Middle East & Africa
10.1 Middle East & Africa Immune Mediated Tumor Killing Assays Service Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Immune Mediated Tumor Killing Assays Service Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Immune Mediated Tumor Killing Assays Service 麻豆原创 Size by Country
10.3.1 Middle East & Africa Immune Mediated Tumor Killing Assays Service Consumption Value by Country (2020-2031)
10.3.2 Turkey Immune Mediated Tumor Killing Assays Service 麻豆原创 Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Immune Mediated Tumor Killing Assays Service 麻豆原创 Size and Forecast (2020-2031)
10.3.4 UAE Immune Mediated Tumor Killing Assays Service 麻豆原创 Size and Forecast (2020-2031)
11 麻豆原创 Dynamics
11.1 Immune Mediated Tumor Killing Assays Service 麻豆原创 Drivers
11.2 Immune Mediated Tumor Killing Assays Service 麻豆原创 Restraints
11.3 Immune Mediated Tumor Killing Assays Service Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Immune Mediated Tumor Killing Assays Service Industry Chain
12.2 Immune Mediated Tumor Killing Assays Service Upstream Analysis
12.3 Immune Mediated Tumor Killing Assays Service Midstream Analysis
12.4 Immune Mediated Tumor Killing Assays Service Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Agilent
Laboratories
Explicyte
Reaction Biology
Axion BioSystems
Sartorius
ICE Bioscience
Shanghai Saily Biotechnology
ProBio
Charles River
Imodels
Xeno Diagnostics
Cyagen
MarinBio
Pharmalegacy
Celentyx
Crown Bioscience
Cellomatics Biosciences
听
听
*If Applicable.